Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report

Epidermal growth factor receptor (EGFR) mutation is a favorable prognostic factor of non-small cell lung cancer (NSCLC). In the majority of patients with EGFR mutations, clinical benefits of EGFR-tyrosine kinase inhibitors (TKIs) have been reported. One of the TKIs, gefitinib, appears to be less tox...

詳細記述

保存先:
書誌詳細
出版年:Exp Ther Med
主要な著者: WATANABE, HIROKO, TAMURA, TOMOHIRO, KAGOHASHI, KATSUNORI, TAKAYASHIKI, NORIO, KURISHIMA, KOICHI, SATOH, HIROAKI, HIZAWA, NOBUYUKI
フォーマット: Artigo
言語:Inglês
出版事項: D.A. Spandidos 2015
主題:
Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4487036/
https://ncbi.nlm.nih.gov/pubmed/26170967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2015.2499
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料